No FDA approval of psilocybin in any indication occurs in 2026; advanced-cancer and grief Phase 3 durability data remain too thin.

The FDA won't approve psilocybin (the active compound in 'magic mushrooms') as a treatment for any medical condition in 2026. The most promising research areas — helping people with terminal cancer anxiety or grief — don't yet have long-term study results showing the effects hold up over time. Without that evidence, the FDA won't approve it. This matters because approval is what would allow doctors to legally prescribe it and insurers to potentially cover it.

Expanding indications lack Phase 3 durability readouts. Without long-term efficacy evidence, the approval bar will not be met within the calendar year.